LRA announces the 2023 recipients of the Lupus Innovation Award during #NationalKidneyMonth as three of this year’s seven award recipients are studying issues that come with this too-common complication. 🧵1of2 https://t.co/VZL9qJu9kF

Updated AAV Treatment Recommendations AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include GPA, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). https://t.co/YCNGYZfSr1 https://t.co/MFs9ykm4fb

Our old friend, hydroxychloroquine Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies: hydroxychloroquine. He outlined how the anti-malarial medication has efficacy and widespread usage in lupus. https://t.co/hKFLg1sogJ https://t.co/OxnbwpWygF

#RNL2023 Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/8bEEC6gt5Z https://t.co/Toy2DxnC4S

Treat to target approach in PsA Systematic rev: 12-43% pts achieved target of very low disease activity or remission Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative @DrLauraCoates at #RNL2023 https://t.co/XyXBAn82F1 https://t.co/W0nVdq6urq

#RNL2023: Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years @RheumNow https://t.co/vPflDm22b2 https://t.co/7Al9I3Eidu

Retrospective study of Apremilast survival in 281 #psoriasis pts(22% w/ PsA) showed 1 yr drug survival=54%, less at 2 yrs (41%), 3 yrs (32%), and 4 yrs (30%). Half 1+ adverse events; D/C mostly for lack of efficacy (27%), adverse events (12%) https://t.co/2dm6H6cYNX https://t.co/F2YtzzWMdT

Phase 3 trial of IV 200 mg qd hydrocortisone in 800 pts admitted to ICU for severe community-acquired pneumonia. Day 28 strongly favored IV Hydrocort vs PBO for mortality (6% v 12%; P=0.006), Mech ventilation (18% vs 29.5%), vasopressors (15% v 25%) https://t.co/TqxorRAuvc https://t.co/0R7kNaKgj5

#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/MZJfg2lM70 https://t.co/eOkcwd4xMz

The Biosimilar "Buy In" Dr. Rachel Tate, @uptotate , shared insights into these key discussions during RheumNow Live. https://t.co/dD3uZCNQEo https://t.co/MuN91Oqbvo

Metformin Reduces Osteoarthritis Risk Metformin may help cut the risk of osteoarthritis (OA) in those with type 2 diabetes, researchers reported. https://t.co/dmyKssbWjO https://t.co/p7lPdjYfbU

Spondyloarthritis Innovations The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it. https://t.co/3JeNeE0EO6 https://t.co/fA1B2TA2xF